Abstract: Triple-negative breast cancer (TNBC) is a heterogeneous disease. Recently, the development of a gene expression profile fa-cilitated the re-classification of TNBC into six new subtypes, which show varied sensitivities to different therapies. In the era of preci -sion medicine, precision therapy may be directed at various potentially actionable molecular mutations in different subtypes of TNBC.